We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.9B
1-Year Est. Return 169.69%
This Fund
S&P 500
This Quarter Est. Return
+26.15%
1 Year Est. Return
+169.69%
3 Year Est. Return
+507.65%
5 Year Est. Return
+746.04%
10 Year Est. Return
–
AUM
$2.9B
AUM Growth
+$433M
Cap. Flow
-$46.5M
Cap. Flow %
-1.6%
Top 10 Hldgs %
48.91%
Holding
114
New
21
Increased
25
Reduced
41
Closed
17

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$81.1M
2
INSP icon
Inspire Medical Systems
INSP
+$64.3M
3
RIGL icon
Rigel Pharmaceuticals
RIGL
+$56.6M
4
CELC icon
Celcuity
CELC
+$48.5M
5
PBLS
Parabilis Medicines Inc
PBLS
+$40.5M

Top Sells

Rank Stock Value
1
TWST icon
Twist Bioscience
TWST
+$73M
2
KRYS icon
Krystal Biotech
KRYS
+$63.9M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$48.4M
4
TGTX icon
TG Therapeutics
TGTX
+$45.1M
5
VCEL icon
Vericel Corp
VCEL
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTMX icon
101
CytomX Therapeutics
CTMX
$808M
– –
-300,000
Closed -$1.41M
DXCM icon
102
DexCom
DXCM
$33.2B
– –
-140,000
Closed -$8.79M
ETON icon
103
Eton Pharmaceutcials
ETON
$1.67B
– –
-166,381
Closed -$4.11M
ICLR icon
104
Icon
ICLR
$12.7B
– –
-192,000
Closed -$21.2M
INBX icon
105
Inhibrx
INBX
$1.78B
– –
-131,000
Closed -$8.81M
JSPR icon
106
Jasper Therapeutics
JSPR
$23.6M
– –
-276,312
Closed -$242K
PCVX icon
107
Vaxcyte
PCVX
$9.1B
– –
-385,472
Closed -$22.4M
STAA icon
108
STAAR Surgical
STAA
$1.18B
– –
-20,000
Closed -$374K
TVTX icon
109
Travere Therapeutics
TVTX
$6.15B
– –
-546,000
Closed -$16.2M
TYRA icon
110
Tyra Biosciences
TYRA
$1.71B
– –
-10,000
Closed -$383K
ZYME icon
111
Zymeworks
ZYME
$2.09B
– –
-10,000
Closed -$250K
RAPP
112
Rapport Therapeutics
RAPP
$2.2B
– –
-10,000
Closed -$313K
ORKA
113
Oruka Therapeutics
ORKA
$6.13B
– –
-5,000
Closed -$245K
LBRX
114
LB Pharmaceuticals
LBRX
$1.59B
– –
-10,000
Closed -$247K
1 2 3 4
5

Similar funds

GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
7WCP
71 West Capital Partners Boston, Massachusetts $2.89B AUM
ACM
Aquatic Capital Management Chicago, Illinois $2.91B AUM 27.09% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.91B AUM 24.25% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.89B AUM 29.25% 1-Year Est. Return
WPW
Waldron Private Wealth Bridgeville, Pennsylvania $2.89B AUM 23.18% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Soleus Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Soleus Capital Management held 114 positions worth $2.9B, up 18% from $2.47B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Soleus Capital Management's Q2 2026 filing shows 21 new, 25 increased, 41 reduced and 17 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M. The largest sale was Twist Bioscience, an estimated $73M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Soleus Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M.
  • Soleus Capital Management added most to Insulet in Q2 2026, an estimated $81.1M increase.
  • Soleus Capital Management's biggest Q2 2026 reduction was Twist Bioscience, cutting an estimated $73M.
  • Soleus Capital Management fully exited Vaxcyte in Q2 2026, selling an estimated $22.4M.
  • Soleus Capital Management's ten largest holdings make up 49% of its $2.9B portfolio in Q2 2026.
  • Soleus Capital Management opened 21 new positions and closed 17 in Q2 2026.
  • Soleus Capital Management's portfolio value rose 18% quarter-over-quarter to $2.9B.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.